NCT04868344View on ClinicalTrials.gov

A Study of MRG003 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

March 29, 2021

Study Completion Date

March 29, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

MRG003

Administered intravenously

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Shanghai Miracogen Inc.

INDUSTRY

NCT04868344 - A Study of MRG003 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter